IGF1 and acromegaly: Among CAM2029-treated patients, it was notable that those who discontinued treatment due to AEs prior to week 22 and were regarded as nonresponders in the primary and secondary analyses had IGF-1 ≤ULN at their final assessment before switching back to their previous treatment for acromegaly.